title: Therapeutic potential of endothelin receptor antagonism in kidney disease.
abstract: Our growing understanding of the role of the endothelin (ET) system in renal physiology and pathophysiology is from emerging studies of renal disease in animal models and humans. ET receptor antagonists reduce blood pressure and proteinuria in chronic kidney disease and cause regression of renal injury in animals. However, the therapeutic potential of ET receptor antagonism has not been fully explored and clinical studies have been largely limited to patients with diabetic nephropathy. There remains a need for more work in nondiabetic chronic kidney disease, end-stage renal disease (patients requiring maintenance dialysis and those with a functioning kidney transplant), ischemia reperfusion injury, and sickle cell disease. The current review summarizes the most recent advances in both preclinical and clinical studies of ET receptor antagonists in the field of kidney disease.
authors.affiliation: University/British Heart Foundation Centre of Research Excellence, University of Edinburgh; and The Queen's Medical Research Institute, Edinburgh; and.
authors.forename: Alicja
authors.initials: A
authors.lastname: Czopek
authors.affiliation: University/British Heart Foundation Centre of Research Excellence, University of Edinburgh; and The Queen's Medical Research Institute, Edinburgh; and.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Moorhouse
authors.affiliation: University/British Heart Foundation Centre of Research Excellence, University of Edinburgh; and The Queen's Medical Research Institute, Edinburgh; and.
authors.forename: David J
authors.initials: DJ
authors.lastname: Webb
authors.affiliation: University/British Heart Foundation Centre of Research Excellence, University of Edinburgh; and The Queen's Medical Research Institute, Edinburgh; and Department of Renal Medicine, Royal Infirmary of Edinburgh, United Kingdom bean.dhaun@ed.ac.uk.
authors.forename: Neeraj
authors.initials: N
authors.lastname: Dhaun
mesh_terms: D000818:Animals; D065128:Endothelin Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D016232:Endothelins / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D007674:Kidney Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008024:Ligands; D017466:Receptors, Endothelin / Q000187:drug effects* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D008024:Ligands; D017466:Receptors, Endothelin
keywords: endothelin; kidney; therapeutics